Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials

MLA

Matthew Rashid, et al. “Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials.” Journal of Urologic Oncology, vol. 22, no. 3, Nov. 2024, pp. 211–23. EBSCOhost, https://doi.org/10.22465/juo.244800520026.

APA

Matthew Rashid, Eli Oldham, Griffin K. Hughes, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ryan McIntire, Bradley Johnson, Jordan Tuia, Alyson Haslam, Vinay Prasad, & Matt Vassar. (2024). Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials. Journal of Urologic Oncology, 22(3), 211–223. https://doi.org/10.22465/juo.244800520026

Chicago

Matthew Rashid, Eli Oldham, Griffin K. Hughes, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ryan McIntire, et al. 2024. “Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials.” Journal of Urologic Oncology 22 (3): 211–23. doi:10.22465/juo.244800520026.